Basilea Pharmaceutica Ltd (BSLN):企業の財務・戦略的SWOT分析

◆英語タイトル:Basilea Pharmaceutica Ltd (BSLN) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH61547FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年4月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スイス
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD600 ⇒換算¥66,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD900 ⇒換算¥99,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Basilea Pharmaceutica Ltd (Basilea) is a biopharmaceutical company that develops and markets antibiotics, antifungals and oncology drugs. The company’s products address increasing resistance and non-response to present treatment options for various therapeutic areas such as cancer, bacterial infections and fungal infections. Basilea also conducts research in the areas of anti-infectives, cancer and bacterial or fungal strains. It discovers drugs with the help of various technologies such as genomics, assay development, cell biology, and others. The company also operates in France, the UK, China, Germany, Spain, Switzerland, Italy and Denmark. Basilea is headquartered in Basel, Switzerland.

Basilea Pharmaceutica Ltd Key Recent Developments

Apr 01,2021: Basilea announces closing of previously announced transaction regarding divestment of its Chinese R&D subsidiary
Mar 24,2021: Basilea reports positive interim results from phase 2 study FIDES-01 for derazantinib in FGFR2 gene mutation- or amplification-positive patients with bile duct cancer (iCCA)
Feb 16,2021: Basilea reports strong 2020 financial results and significant progress in the clinical pipeline of its oncology assets
Feb 12,2021: Basilea präsentiert auf ASCO GU Symposium Dosisfindungs-Ergebnisse für Derazantinib/PD-L1-Checkpoint-Inhibitor-Kombination aus FIDES-02-Studie für Patienten mit soliden Tumoren
Feb 11,2021: Basilea achieves preclinical milestone in oncology collaboration on potential first-in-class kinase inhibitor

This comprehensive SWOT profile of Basilea Pharmaceutica Ltd provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of GlobalData’s ‘Profile on Demand’ service, covering over 50,000 of the world’s leading companies. Once purchased, GlobalData’s highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Basilea Pharmaceutica Ltd including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).

The profile contains critical company information including*,

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note*: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include,

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

【レポートの目次】

Table of Contents

Section 1 – About the Company

Basilea Pharmaceutica Ltd – Key Information
Basilea Pharmaceutica Ltd – Overview
Basilea Pharmaceutica Ltd – Key Employees
Basilea Pharmaceutica Ltd – Key Employee Biographies
Basilea Pharmaceutica Ltd – Key Operational Heads
Basilea Pharmaceutica Ltd – Major Products and Services
Basilea Pharmaceutica Ltd – History
Basilea Pharmaceutica Ltd – Company Statement
Basilea Pharmaceutica Ltd – Locations And Subsidiaries
Basilea Pharmaceutica Ltd
Head Office
Other Locations & Subsidiaries

Section 2 – Company Analysis

Basilea Pharmaceutica Ltd – Business Description
Basilea Pharmaceutica Ltd – Corporate Strategy
Basilea Pharmaceutica Ltd – SWOT Analysis
SWOT Analysis – Overview
Basilea Pharmaceutica Ltd – Strengths
Basilea Pharmaceutica Ltd – Weaknesses
Basilea Pharmaceutica Ltd – Opportunities
Basilea Pharmaceutica Ltd – Threats
Basilea Pharmaceutica Ltd – Key Competitors

Section 3 – Company Financial Performance Charts

Basilea Pharmaceutica Ltd – Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts

Section 4 – Appendix

Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

Note*: Some sections may be missing if data is unavailable for the company

List of Tables

Basilea Pharmaceutica Ltd, Key Information
Basilea Pharmaceutica Ltd, Key Ratios
Basilea Pharmaceutica Ltd, Share Data
Basilea Pharmaceutica Ltd, Major Products and Services
Basilea Pharmaceutica Ltd, History
Basilea Pharmaceutica Ltd, Key Employees
Basilea Pharmaceutica Ltd, Key Employee Biographies
Basilea Pharmaceutica Ltd, Key Operational Heads
Basilea Pharmaceutica Ltd, Other Locations
Basilea Pharmaceutica Ltd, Subsidiaries
Basilea Pharmaceutica Ltd, Key Competitors
Basilea Pharmaceutica Ltd, SWOT Analysis
Basilea Pharmaceutica Ltd, Ratios based on current share price
Basilea Pharmaceutica Ltd, Annual Ratios
Basilea Pharmaceutica Ltd, Interim Ratios
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[Basilea Pharmaceutica Ltd (BSLN):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Elsalys Biotech SAS-製薬・医療分野:企業M&A・提携分析
    Summary Elsalys Biotech SAS (Elsalys Biotech) is a biotechnology company that designs and develops therapeutic antibodies in oncology and ophthalmology. The company's pipeline products include monoclonal antibodies designed to fight against cancers, vascular eye, idiopathic pulmonary fibrosis and ch …
  • Eisai Co Ltd (4523):企業の財務・戦略的SWOT分析
    Eisai Co Ltd (4523) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • The Boeing Co (BA):企業の財務・戦略的SWOT分析
    The Boeing Co (BA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Immatics Biotechnologies GmbH-製薬・医療分野:企業M&A・提携分析
    Summary Immatics Biotechnologies GmbH (Immatics) is a clinical stage biopharmaceutical company that develops drugs for the treatment of cancer. It develops peptide based active immunotherapy drug candidates based on it novel technology, XPRESIDENT discovery platform. The company has active programs …
  • Ergon, Inc.:石油・ガス:M&Aディール及び事業提携情報
    Summary Ergon Inc (Ergon) is an integrated energy company that carries out the exploration and production of crude oil and natural gas, processing, transportation and terminaling of crude oil, storage, marketing and distribution of specialty petroleum products. The company also manufactures and mark …
  • WellSky Corp:企業の戦略的SWOT分析
    WellSky Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Mercachem Holding bv:製薬・医療:M&Aディール及び事業提携情報
    Summary Mercachem Holding BV (Mercachem) is a research company that offers transparent chemistry services. The company provides services in the areas of discovery chemistry, medicinal chemistry, parallel chemistry and process research. Its parallel chemistry services include library design, chemical …
  • Scholar Rock Inc-製薬・医療分野:企業M&A・提携分析
    Summary Scholar Rock Inc (Scholar Rock), a subsidiary of Scholar Rock LLC is a biotechnology company that discovers and develops biologic therapies. It develops niche activators, modulating supracellular activation, for the application in the treatment of diseases such as fibrosis, diseases of muscu …
  • Lantern Pharma Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Lantern Pharma Inc (Lantern Pharma) is a clinical stage pharmaceutical company that discovers and develops therapies for various cancer types. The company’s pipeline products Irofulven-1 and Irofulven-2 are non-hormone, non-chemotherapy, next-generation DNA damage repair inhibitors. Its othe …
  • Yanbu National Petrochemicals Co (2290):企業の財務・戦略的SWOT分析
    Summary Yanbu National Petrochemicals Co (YANSAB), a subsidiary of Saudi Basic Industries Corp is a manufacturer and distributor of petrochemical products. The company offers products such as ethylene, linear density polyethylene, polypropylene, butene 1, ethylene glycol, polyethylene, butene 2, MTB …
  • Olvi plc:企業の戦略・SWOT・財務情報
    Olvi plc - Strategy, SWOT and Corporate Finance Report Summary Olvi plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • Heijmans NV:企業の戦略・SWOT・財務情報
    Heijmans NV - Strategy, SWOT and Corporate Finance Report Summary Heijmans NV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • ASUSTeK Computer Inc.:企業の戦略・SWOT・財務分析
    ASUSTeK Computer Inc. - Strategy, SWOT and Corporate Finance Report Summary ASUSTeK Computer Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Berjaya Corporation Berhad (BJCORP):企業の財務・戦略的SWOT分析
    Berjaya Corporation Berhad (BJCORP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • WEX Pharmaceuticals Inc:企業の戦略的SWOT分析
    WEX Pharmaceuticals Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • Sillajen Biotherapeutics (215600):製薬・医療:M&Aディール及び事業提携情報
    Summary Sillajen Biotherapeutics (SillaJen), formerly SillaJen Inc, is a biotechnology company that designs and develops oncolytic immunotherapeutics for the treatment of cancer. The company’s pipeline products comprise Pexa-Vec, an oncolytic immunotherapeutic virus which is in Phase III trial that …
  • Digital Realty Trust Inc:企業のM&A・事業提携・投資動向
    Digital Realty Trust Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Digital Realty Trust Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisiti …
  • EVN AG:発電所・企業SWOT分析
    EVN AG - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (executives) …
  • Covagen AG-製薬・医療分野:企業M&A・提携分析
    Summary Covagen AG (Covagen), a subsidiary of Cilag GmbH International is a biopharmaceutical company specializing in the development of multispecific protein therapeutics through the FynomAb technology. The company’s pipeline products include COVA 322, a bispecific anti-tumor necrosis factor alpha …
  • Kohlberg Kravis Roberts & Co LP:企業のM&A・事業提携・投資動向
    Kohlberg Kravis Roberts & Co LP - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Kohlberg Kravis Roberts & Co LP Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆